Neurol. praxi. 2020;21(3):203-208 | DOI: 10.36290/neu.2020.074

Multiple sclerosis (MS) is autoimmune disorder affecting the central nervous system

MUDr. Miriam Fedičová, MUDr. Marianna Vitková, PhD., doc. MUDr. Jarmila Szilasiová, PhD., prof. MUDr. Zuzana Gdovinová, CSc., FESO, FEAN
Neurologická klinika UNLP a LF UPJŠ, Košice

Currently, we have a fairly wide range of disease - modifying drugs (DMD) with different mechanisms of action and different efficiencies. To obtain the most efficient therapeutic results we need to choose an individual approach for appropriate therapy. It is also very important to keep in mind the risk of this therapy for appropriate patient. The continual clinical and laboratory monitoring of the patients is unavoidable.

Keywords: multiple sclerosis, disease modifying therapy (DMT).

Published: June 18, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fedičová M, Vitková M, Szilasiová J, Gdovinová Z. Multiple sclerosis (MS) is autoimmune disorder affecting the central nervous system. Neurol. praxi. 2020;21(3):203-208. doi: 10.36290/neu.2020.074.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012; 366: 1870-1880. Go to original source... Go to PubMed...
    2. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380: 1819-1828. Go to original source... Go to PubMed...
    3. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380: 1829-1839. Go to original source... Go to PubMed...
    4. Dostupné z https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis_en.pdf. [cit. 2019-12-01].
    5. Dubey D, Cano CA, Stuve O. Intractable and highly active relapsing multiple sclerosis role of alemtuzumab. Neuropsychiatr Dis Treat. 2015; 11: 2405. Go to original source... Go to PubMed...
    6. Ermis U, Weis J, Schulz JBN. PML in a patient treated with fumaric acid. Engl J Med. 2013; 368(17): 1657-1658. Go to original source... Go to PubMed...
    7. Greenberg BM, Khatri BO, Kramer JF. Current and emerging multiple sclerosis therapeutics. Continuum (Minneap Minn). 2010; 16: 58-77. Go to original source... Go to PubMed...
    8. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995; 45: 1277-1285. Dostupné z [online] [cit. 2019-12-01]: https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis_en.pdf. Go to PubMed...
    9. Khatri BO. Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long - term experience and an update on the clinical evidence. Ther Adv Neurol Disord. 2016; 9(2): 130-147. Go to original source... Go to PubMed...
    10. Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharm. 2011; 34: 28-35. Go to original source... Go to PubMed...
    11. Limmroth V, Malessa R, Zettl UK, Koehler J, Japp G, Haller P, Elias W, Obhof W, Viehöver A, Meier U, Brosig A, Hasford J, Putzki N, Kalski G, Wernsdörfer C; QUASIMS Study Group. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol. 2007; 254: 67-77. Go to original source... Go to PubMed...
    12. Lublin FD, Whitaker JN, Eidelman BH. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12-18. Go to original source... Go to PubMed...
    13. Nielsen NM, Rostgaard K, Rasmussen S, Koch-Henriksen N, Storm HH, Melbey M, Hjalgrim H. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer. 2006; 118: 979-984. Go to original source... Go to PubMed...
    14. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2003; CD002047. Go to original source...
    15. Patten SB, Metz LM. Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler. 2001; 7: 243-248. Go to original source... Go to PubMed...
    16. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9): 899-910. Go to original source... Go to PubMed...
    17. Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol. 2014; 175: 397-407. Go to original source... Go to PubMed...
    18. Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol. 2010; 257: 2020-2023. Go to original source... Go to PubMed...
    19. Sartori A, Carle D, Freedman MS. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. Expert Opin Pharmacother. 2014; 15(7): 1019-1027. Go to original source... Go to PubMed...
    20. US Food Drug Administration Tysabri. 1-1-2015. Ref Type: Online Source. [cit. 2019-11-30].
    21. Vukusic S, Coyle K P, Jurgensen S, Truffinet P, Benamor M, Afsar S, Purvis A, Poole ME, Chambers Ch. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. Multiple Sclerosis Journal 2019; 1-8. Go to original source... Go to PubMed...
    22. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622-1627. Go to original source... Go to PubMed...
    23. Warnatz K, Peter HH, Schumacher M, Wiese L, Prasse A, Petschner F, Vaith P, Volk B, Weiner SM. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis. 2003; 62: 50-57. Go to original source... Go to PubMed...
    24. Ziemssen T, Ashtamker N, Rubinchick S, Knappertz V, Comi G. Long-term safety and tolerability of glatiramer acetate 20 mg in the treatment of relapsing forms of multiple sclerosis. Expert Opin Drug Saf. 2016 Dec 17. [Epub ahead of print]. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.